Found: 1
Select item for more details and to access through your institution.
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 700, doi. 10.1007/s10637-015-0238-2
- By:
- Publication type:
- Article